| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study
|
Rossi, Emma C
|
|
|
18 |
3 |
p. 384-392
|
artikel
|
| 2 |
Adjuvant ipilimumab for stage III melanoma: the patient voice
|
Brundage, Michael
|
|
|
18 |
3 |
p. 282-284
|
artikel
|
| 3 |
Anal cancer: leading the way
|
Habr-Gama, Angelita
|
|
|
18 |
3 |
p. 276-277
|
artikel
|
| 4 |
Another treatment option for relapsed or refractory chronic lymphocytic leukaemia
|
Mauro, Francesca R
|
|
|
18 |
3 |
p. 270-271
|
artikel
|
| 5 |
Anti-angiogenesis: disappointment in localised oesophagogastric cancer
|
Lordick, Florian
|
|
|
18 |
3 |
p. 278-279
|
artikel
|
| 6 |
Azathioprine associated with myeloid neoplasm risk
|
Burki, Talha Khan
|
|
|
18 |
3 |
p. e140
|
artikel
|
| 7 |
Barriers to, and opportunities for, palliative care development in the Eastern Mediterranean Region
|
Fadhil, Ibtihal
|
|
|
18 |
3 |
p. e176-e184
|
artikel
|
| 8 |
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial
|
Glynne-Jones, Robert
|
|
|
18 |
3 |
p. 347-356
|
artikel
|
| 9 |
Bicalutamide with radiotherapy for prostate cancer
|
Brower, Vicki
|
|
|
18 |
3 |
p. e141
|
artikel
|
| 10 |
Bringing the “SunSmart” message to smart phones
|
Jenkins, Emily
|
|
|
18 |
3 |
p. 293
|
artikel
|
| 11 |
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial
|
Soulières, Denis
|
|
|
18 |
3 |
p. 323-335
|
artikel
|
| 12 |
Buparlisib—and the continued quest for the ideal cure
|
Worden, Francis P
|
|
|
18 |
3 |
p. 273-274
|
artikel
|
| 13 |
Cancer care on Palm Island, Australia
|
Kenyon, Georgina
|
|
|
18 |
3 |
p. 291-292
|
artikel
|
| 14 |
C/Can 2025: City Cancer Challenge, a new initiative to improve cancer care in cities
|
Adams, Cary
|
|
|
18 |
3 |
p. 286-287
|
artikel
|
| 15 |
Classic cytotoxic drugs: a narrow path for regulatory approval
|
Pivot, Xavier
|
|
|
18 |
3 |
p. 279-281
|
artikel
|
| 16 |
Correction to Lancet Oncol 2016; 17: 234–42
|
|
|
|
18 |
3 |
p. e134
|
artikel
|
| 17 |
Correction to Lancet Oncol 2016; 17: e506
|
|
|
|
18 |
3 |
p. e134
|
artikel
|
| 18 |
Cristina
|
Blott, Jonathan
|
|
|
18 |
3 |
p. 294
|
artikel
|
| 19 |
Different faces. Same fight: Project 3.8
|
Swain, Kelley
|
|
|
18 |
3 |
p. 295
|
artikel
|
| 20 |
Gastrointestinal stromal tumour detection with somatostatin receptor imaging, 68Ga-HA-DOTATATE PET–CT
|
Braat, Arthur J A T
|
|
|
18 |
3 |
p. e185
|
artikel
|
| 21 |
Genomic-adjusted radiation dose
|
Spratt, Daniel E
|
|
|
18 |
3 |
p. e127
|
artikel
|
| 22 |
Genomic-adjusted radiation dose
|
Kunkler, Ian
|
|
|
18 |
3 |
p. e128
|
artikel
|
| 23 |
Genomic-adjusted radiation dose – Authors' reply
|
Scott, Jacob G
|
|
|
18 |
3 |
p. e129
|
artikel
|
| 24 |
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
|
Coens, Corneel
|
|
|
18 |
3 |
p. 393-403
|
artikel
|
| 25 |
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
|
Zelenetz, Andrew D
|
|
|
18 |
3 |
p. 297-311
|
artikel
|
| 26 |
Immune therapy meets precision medicine
|
Shariat, Shahrokh F
|
|
|
18 |
3 |
p. 271-273
|
artikel
|
| 27 |
Intermittent sunitinib for metastatic renal cell carcinoma
|
Venkatesan, Priya
|
|
|
18 |
3 |
p. e139
|
artikel
|
| 28 |
Intermittent vismodegib dosing to treat multiple basal-cell carcinomas
|
Mosterd, Klara
|
|
|
18 |
3 |
p. 284-286
|
artikel
|
| 29 |
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
|
Seymour, Lesley
|
|
|
18 |
3 |
p. e143-e152
|
artikel
|
| 30 |
Journal club: epigenetic profiling to classify cancer of unknown primary
|
Perone, Ylenia
|
|
|
18 |
3 |
p. e130
|
artikel
|
| 31 |
Journal club: epigenetic profiling to classify cancer of unknown primary – Authors' reply
|
Moran, Sebastian
|
|
|
18 |
3 |
p. e131
|
artikel
|
| 32 |
Letrozole not superior to anastrozole for early breast cancer
|
Brower, Vicki
|
|
|
18 |
3 |
p. e138
|
artikel
|
| 33 |
Mind the gap: charity and crowdfunding in health care
|
The Lancet Oncology,
|
|
|
18 |
3 |
p. 269
|
artikel
|
| 34 |
NICE guidance on ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia in the presence of 17p deletion or TP53 mutation
|
Mikudina, Boglarka
|
|
|
18 |
3 |
p. 289-290
|
artikel
|
| 35 |
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|
Sharma, Padmanee
|
|
|
18 |
3 |
p. 312-322
|
artikel
|
| 36 |
Novel mutations in cervical cancer
|
Burki, Talha Khan
|
|
|
18 |
3 |
p. e137
|
artikel
|
| 37 |
Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial
|
Erlandsson, Johan
|
|
|
18 |
3 |
p. 336-346
|
artikel
|
| 38 |
Participation in psychosocial oncology and quality-of-life research: a systematic review
|
Wakefield, Claire E
|
|
|
18 |
3 |
p. e153-e165
|
artikel
|
| 39 |
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
|
Cunningham, David
|
|
|
18 |
3 |
p. 357-370
|
artikel
|
| 40 |
Reduced carcinogens found in e-cigarette users
|
Burki, Talha Khan
|
|
|
18 |
3 |
p. e142
|
artikel
|
| 41 |
See me, hear me, heal me
|
Holmes, Bob
|
|
|
18 |
3 |
p. 296
|
artikel
|
| 42 |
Sentinel-lymph-node mapping in endometrial cancer: routine practice?
|
Amant, Frédéric
|
|
|
18 |
3 |
p. 281-282
|
artikel
|
| 43 |
Short-course radiotherapy with delayed surgery for rectal cancer: a third option
|
Bujko, Krzysztof
|
|
|
18 |
3 |
p. 275-276
|
artikel
|
| 44 |
Soft tissue sarcomas in adolescents and young adults: a comparison with their paediatric and adult counterparts
|
van der Graaf, Winette T A
|
|
|
18 |
3 |
p. e166-e175
|
artikel
|
| 45 |
The drama of prostate cancer diagnostics
|
Bratt, Ola
|
|
|
18 |
3 |
p. e132
|
artikel
|
| 46 |
The drama of prostate cancer diagnostics – Authors' reply
|
Iversen, Peter
|
|
|
18 |
3 |
p. e133
|
artikel
|
| 47 |
Through the Dark
|
Martin, Hannah
|
|
|
18 |
3 |
p. 293-294
|
artikel
|
| 48 |
Treatment options not taken for non-small-cell lung cancer
|
Burki, Talha Khan
|
|
|
18 |
3 |
p. e135
|
artikel
|
| 49 |
Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial
|
Dréno, Brigitte
|
|
|
18 |
3 |
p. 404-412
|
artikel
|
| 50 |
Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial
|
Zhang, Pin
|
|
|
18 |
3 |
p. 371-383
|
artikel
|
| 51 |
Venetoclax active and safe in non-Hodgkin lymphoma
|
Das, Manjulika
|
|
|
18 |
3 |
p. e136
|
artikel
|
| 52 |
Will drug companies' price-transparency efforts fall short?
|
Furlow, Bryant
|
|
|
18 |
3 |
p. 288
|
artikel
|
Tijdschrift beschrijving